患有H3K27M突变扩散中线质瘤的儿童和成年人生存预测的差异
Xuan Gong1,2, Shuwen Kuang3, Dongfeng Deng3
1Departments of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
CNS neuroscience & therapeutics
|June 13, 2023
概括
在儿童和成年人之间,H3K27M突变扩散中线质瘤 (DMG) 的存活率显著不同. 预后因素因年龄而异,凸显了DMG治疗中需要基于年龄的临床和分子分层.
科学领域:
- 神经瘤学神经瘤学
- 儿科瘤学 儿科瘤学
- 中枢神经系统瘤 中枢神经系统瘤
背景情况:
- H3K27M突变扩散中线质瘤 (DMG) 是一种罕见的,攻击性的中枢神经系统瘤.
- 生物学行为,特征和预后尚未完全理解,特别是在成年人中.
- 这项研究解决了这些知识差距.
研究的目的:
- 研究H3K27M突变型DMG的临床病理特征.
- 单独确定儿科和成人患者的预后因素.
- 告知特定年龄的治疗策略.
主要方法:
- 对171名H3K27M突变的DMG患者进行了回顾性分析.
- 根据年龄分层的临床病理学数据 (儿科与成人).
- 考克斯比例危险模型用于预后因素识别.
主要成果:
- 该队列的平均整体存活时间 (OS) 为9.0个月.
- 成年人比儿童 (7.1个月) 的生存期更长 (12.3个月).
- 有利的预后因素包括成人年龄,单一病变,放射治疗和完整的ATRX;预后因素因年龄组而异.
结论:
- 在儿科和成人H3K27M突变DMG之间,临床病理特征和预后存在显著差异.
- 基于年龄的分层对临床和分子方法至关重要.
- 进一步的研究应该专注于特定年龄的治疗目标.
相关概念视频
Comparing the Survival Analysis of Two or More Groups
228
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
228
Cancer Survival Analysis
402
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
402
Kaplan-Meier Approach
195
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
195


